Disease Overview：Focal Segmental Glomerulosclerosis（FSGS）
Focal Segmental Glomerulosclerosis (FSGS) is a histopathological pattern of kidney injury characterized by scarring (sclerosis) affecting only some glomeruli (focal) and involving only portions of individual glomeruli (segmental). It represents a leading cause of nephrotic syndrome in adults and children, often progressing to end-stage kidney disease if uncontrolled. FSGS may arise from genetic mutations, adaptive responses to hyperfiltration, viral triggers (e.g., HIV), or autoimmune mechanisms—and in many cases remains idiopathic. Diagnosis requires renal biopsy with light, immunofluorescence, and electron microscopy to distinguish primary (podocyte-centric) from secondary forms. Management hinges on risk stratification: corticosteroids and calcineurin inhibitors remain first-line for steroid-sensitive cases, while newer agents—including B-cell–targeted biologics (e.g., rituximab) and podocyte-stabilizing therapies under clinical investigation—are increasingly deployed in refractory disease. Prognosis varies widely; persistent proteinuria >1 g/day and declining eGFR signal higher progression risk.
China offers distinct advantages in FSGS care: its top-tier nephrology centers—such as Peking University First Hospital and Shanghai Renji Hospital—combine deep expertise in glomerular disease with advanced diagnostic capabilities, including high-resolution electron microscopy and next-generation sequencing for genetic subtyping. Robust clinical trial participation ensures timely access to emerging therapeutics. Published cohort studies demonstrate comparable remission rates to Western benchmarks, particularly in steroid-resistant pediatric FSGS managed with tailored immunomodulation. Crucially, treatment costs—including biopsy, genomic testing, and 6-month immunosuppressive regimens—are typically 40–60% lower than in the US or EU, without compromising protocol fidelity or monitoring intensity. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: pre-arrival eligibility assessment, direct coordination with certified nephrology units, all-inclusive transparent pricing (covering consultations, diagnostics, medications, and follow-up telemedicine), and multilingual concierge support—from visa assistance to accommodation and interpreter services—ensuring continuity of care and informed decision-making throughout the treatment pathway.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Focal Segmental Glomerulosclerosis (FSGS)
Non-Surgical / Conservative Management
*Target Criteria:* Primary FSGS with proteinuria ≥1 g/day, eGFR ≥30 mL/min/1.73m², no contraindications to immunosuppression.
- •First-line Therapy (Corticosteroids + Calcineurin Inhibitors)
- *Tacrolimus (12-month course, therapeutic drug monitoring)*: ¥4,200–¥6,800 ($590–$950) - *Renal biopsy (diagnostic confirmation & baseline)*: ¥1,800–¥2,500 ($250–$350) - *Monthly labs (serum creatinine, albumin, tacrolimus trough, LFTs, CBC)*: ¥320–¥480/month ($45–$67) - *24-hour urine protein quantification (q3mo)*: ¥180–¥260 ($25–$36)
- •Second-line (Rituximab-based regimens)
- *Pre-infusion workup (Hep B/C serology, CD19 count, ECG)*: ¥650–¥920 ($91–$129) - *Post-infusion monitoring (IgG, CD19, infection panel q1mo × 6)*: ¥2,100–¥3,300 ($295–$465)
Surgical / Procedural Interventions
*Eligibility:* Refractory nephrotic syndrome (proteinuria >3.5 g/day × 6 months), progressive eGFR decline (<15 mL/min/1.73m²), or dialysis dependence.
- •Kidney Transplantation (Deceased Donor)
- *Transplant surgery + hospitalization (14 days)*: ¥245,000–¥312,000 ($34,300–$43,700) - *Induction therapy (ATG or basiliximab)*: ¥4,500–¥7,200 ($630–$1,010) - *1-year maintenance immunosuppression (tacrolimus + MMF + prednisone)*: ¥18,600–¥23,400 ($2,600–$3,280)
Special/Complex Condition Management
- •Genetic FSGS (e.g., *TRPC6*, *INF2* mutations): Genetic testing (NGS panel): ¥3,200–¥4,800 ($450–$670); no immunosuppression indicated — supportive care only.
- •Recurrent FSGS post-transplant: Plasmapheresis (10 sessions): ¥15,200–¥19,800 ($2,130–$2,770); rituximab rescue: ¥8,400–¥12,600 ($1,180–$1,770).
- •Steroid-resistant FSGS with rapid progression: High-dose cyclophosphamide (6-month IV course): ¥3,900–¥5,700 ($550–$800) + hemorrhagic cystitis prophylaxis (mesna): ¥1,100–¥1,600 ($155–$225).
Quick Selection Guide
- •Young adult (<40), low-moderate income, steroid-sensitive: Start prednisone + tacrolimus — total 12-month cost: $2,200–$3,100.
- •Middle-aged (40–65), comorbid diabetes/hypertension, steroid-resistant: Rituximab regimen — total 6-month cost: $2,800–$3,900.
- •Elderly (>70) or frail, eGFR <15 mL/min: Preemptive transplant evaluation if fit; otherwise, palliative conservative management — monthly cost: $180–$260.
- •Recurrent FSGS post-transplant: Urgent plasmapheresis + rituximab — 4-week intensive phase: $4,200–$5,500.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Focal Segmental Glomerulosclerosis Medical Vacation Packages
Curated transparent all-inclusive packages combining Focal Segmental Glomerulosclerosis treatment with China top medical destinations:
